Rx/Dx, Biomarker Licensing Deals Bolster MDxHealth's Shift to Cancer Diagnostics in 2010 | GenomeWeb

Originally published Feb. 21.

After repositioning its business last year to develop cancer diagnostics, MDxHealth's revenues netted from the sale of products and services were boosted by payments from several large pharmaceutical companies with which it has inked biomarker licensing and companion diagnostics deals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

Jeremy Berg is to be the next editor in chief of Science magazine.